Wellness & Lifestyle – Page 3

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

By MedXY 08/01/2025

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Clinical Updates Wellness & Lifestyle

Trimethoprim–Sulfamethoxazole in Pregnancy: No Impact on Birth Weight in a Zimbabwean RCT

By MedXY 08/01/2025

A large randomized trial in Zimbabwe found that trimethoprim–sulfamethoxazole prophylaxis during pregnancy did not significantly increase birth weight or reduce adverse outcomes.

Clinical Updates Wellness & Lifestyle

Durable Efficacy and Long-term Safety of AAV Gene Therapy in Severe Hemophilia B: 13-Year Follow-up Results

By MedXY 08/01/2025

A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.

Clinical Updates Wellness & Lifestyle

Nerandomilast for Idiopathic and Progressive Pulmonary Fibrosis: Phase 3 Trial Insights

By MedXY 08/01/2025

Phase 3 trials demonstrate that nerandomilast, a selective PDE4B inhibitor, significantly slows lung function decline in idiopathic and progressive pulmonary fibrosis over 52 weeks, with manageable safety profiles.

Clinical Updates Wellness & Lifestyle

Corynebacterium diphtheriae Outbreak among Migrants in Europe: Clinical, Epidemiologic, and Microbiologic Insights

By MedXY 08/01/2025

A multicountry outbreak of diphtheria among migrants in Europe raised concerns about cutaneous and respiratory disease, cross-border spread, and emerging antibiotic resistance. Genomic analysis revealed multiclonal transmission and resistance challenges for standard therapies.

Clinical Updates Wellness & Lifestyle

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

By MedXY 08/01/2025

Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.

Clinical Updates Wellness & Lifestyle

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY 08/01/2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.

Clinical Updates Wellness & Lifestyle

Expanding Nonoperative Management in Mismatch Repair–Deficient Early-Stage Solid Tumors: Phase 2 Evidence for Neoadjuvant PD-1 Blockade

By MedXY 08/01/2025

Neoadjuvant PD-1 blockade with dostarlimab enabled organ preservation and high recurrence-free survival in early-stage mismatch repair–deficient (dMMR) solid tumors, extending nonoperative management beyond rectal cancer.

Clinical Updates Wellness & Lifestyle

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

By MedXY 08/01/2025

A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.

Clinical Updates Wellness & Lifestyle

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

By MedXY 08/01/2025

Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.